Lupus anti coagulant
Rachel Jones made this Freedom of Information request to The Joint Committee on Vaccination and Immunisation
Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.
Dear The Joint Committee on Vaccination and Immunisation,
There has been multiple reports of blood clots regarding patients with covid and reports that a high percentage have lupus anti coagulant. I called my doctor to ask if I would be on the underlying health conditions list as I have lupus anticoagulant and they said they didn't think so as its not listed by the JCVI - they did say if I caught covid I would be at increased risk of a blood clot though - how does that make any sense?
Thank you for your email which has been noted. The Secretariat are dealing
with a large volume of queries concerning the advice of JCVI on priority
groups for COVID-19 vaccination and will endeavour to respond queries on
this. Your patience is gratefully appreciated.
JCVI continues to work on the consideration and review of vaccines for
COVID-19 and advice for the COVID-19 vaccination programme and will
publish further advice at the appropriate time.
The latest statement concerning JCVIs advice on this is available at:
The JCVI statement on first dose prioritisation is available at:
The latest published minutes of JCVI meetings are available at:
Further detail on the groups considered a priority and eligible for
COVID-19 vaccination in the first phase of the COVID-19 vaccination
programme is available from the Green Book immunisation against infectious
Disease chapter on COVID-19 at:
Thank you for your email to Public Health England (PHE) on 02 February
2021 regarding you vaccination concerns. I apologies for the delay in
responding, we are currently dealing with a high volume of enquires.
The list of COVID-19 vaccine priority groups has been published by the
Joint Committee on Vaccination and Immunisation. The Joint Committee on
Vaccination and Immunisation (JCVI, the Committee) is an independent
Departmental Expert Committee and a statutory body supported by PHE.
JCVI has advised that for Phase 1 of the COVID-19 Vaccine Programme, the
first priorities should be the prevention of COVID-19 mortality and the
protection of health and social care staff and systems. JCVI has published
the prioritisation list for COVID-19 vaccination which is largely
prioritised by age due to the strong association of older age and
mortality from COVID-19. Those considered clinically extremely vulnerable
have also been prioritised for vaccination and those in clinical risk
groups aged 16 years and over. Please see: priority groups for
coronavirus (COVID-19) vaccination for more information.
Immunisations against Infectious Disease (The Green Book) outlines in more
detail the advice of the JCVI on those who should prioritised and are
eligible for COVID-19 vaccination during the first phase of the programme.
The Green Book is available at:
Details about the current COVID-19 vaccines approved in the UK can be
found through these links, and information is included about the range of
participants in the clinical studies and countries where the vaccine
trials were carried out:
If you have any further questions or concerns about COVID-19 vaccination
please discuss this with your local health care provider.
We hope this information helps.
Enquiries - Public Health England
Rate our service - Click here
www.gov.uk.phe Follow us on Twitter
Protecting and improving the nation’s health
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.Donate Now